Additional Information
Book Details
Abstract
Comprehensive in scope, easy to use, and aligned to the texts you trust, Review of Dermatology, edited by Drs. Ali Alikhan and Thomas L.H. Hocker, is a highly effective study tool for your upcoming board or maintenance exam. Using a concise, bullet-point format and mnemonic devices throughout, this unique guide ensures rapid and efficient recall of the information you need to know for exam success!
- Covers all sub-specialty areas, including general dermatology, dermatopathology, pediatrics, pharmacology, basic science, and dermatologic surgery.
- Maximizes retention and recall by using an outline approach, bullet points, and mnemonic devices that clearly identify key information.
- Illustrates and simplifies complex concepts with more than 400 high-quality clinical images, tables, illustrations, and histopathology slides.
- Keeps you up-to-date with the latest hot-topic developments including new biologic agents used in the treatment of various diseases such as psoriasis, eczema and melanoma.
- Reviews topics you won’t find in any other dermatology study guide, such as genetic alterations and molecular laboratory studies in melanocytic lesions, soft tissue tumors, and other neoplasms.
- Helps you recognize the often-elusive associations between skin diseases and disorders of other organ systems.
- Consult this title on your favorite e-reader, conduct rapid searches, and adjust font sizes for optimal readability.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | cover | ||
| Inside Front Cover | ifc1 | ||
| Review of Dermatology | i | ||
| Copyright Page | iv | ||
| Table Of Contents | v | ||
| Preface | viii | ||
| Purpose of this book | viii | ||
| How the book should be used | viii | ||
| How the book should NOT be used | viii | ||
| Other information | viii | ||
| List of Contributors | ix | ||
| Acknowledgements | xii | ||
| Dedications | xiii | ||
| 1 Basic Science | 1 | ||
| Contents list | 1 | ||
| 1.1 Structure and function of the skin | 1 | ||
| 1.2 Embryology | 11 | ||
| 1.3 Wound healing | 12 | ||
| 1.4 Genetics | 12 | ||
| 1.5 Laboratory techniques and molecular biology | 13 | ||
| 1.6 Ultraviolet light | 13 | ||
| Ultraviolet light (Fig. 1-4) | 13 | ||
| Minimal erythema dose | 13 | ||
| Important definitions | 13 | ||
| 1.7 Immunology | 13 | ||
| 1.7.1 Innate vs adaptive immunity | 13 | ||
| Innate immunity | 13 | ||
| Adaptive immunity | 17 | ||
| 1.7.2 Immunologic mediators | 17 | ||
| Cytokines | 17 | ||
| Toll-like receptors | 17 | ||
| 1.7.3 Complement pathways | 17 | ||
| 1.7.4 Cells of significance | 21 | ||
| 1.7.5 Major histocompatibility complex | 25 | ||
| Further Reading | 25 | ||
| 2 Dermatopharmacology | 27 | ||
| Contents list | 27 | ||
| 2.1 Antihistamines | 27 | ||
| Mechanism of action (MoA) | 27 | ||
| Important facts | 27 | ||
| First-generation H1 antihistamines | 27 | ||
| Second-generation H1 antihistamines | 27 | ||
| Other antihistamines | 27 | ||
| 2.2. Retinoids | 28 | ||
| Introduction | 28 | ||
| Mechanism | 28 | ||
| Side Effects (SEs) of systemic retinoids | 28 | ||
| Mucocutaneous | 28 | ||
| Systemic | 28 | ||
| Labs | 28 | ||
| Hyperlipidemia/hypertriglyceridemia | 28 | ||
| Elevated LFTs | 28 | ||
| Central hypothyroidism (occurs in 80% on bexarotene) | 28 | ||
| Teratogenicity | 28 | ||
| Specific features of RE: | 29 | ||
| Contraindications | 29 | ||
| Interactions | 29 | ||
| 2.3 Corticosteroids (CS) | 31 | ||
| Pharmacology key points (Table 2-3) | 31 | ||
| Adverse effects (systemic) | 31 | ||
| HPA axis suppression (see Box 2-1) | 31 | ||
| Glucocorticoid effects | 32 | ||
| Mineralocorticoid effects (tend to occur with CS with high MC effect) | 32 | ||
| Lipid effects | 32 | ||
| Pediatric effects | 32 | ||
| Bone effects | 32 | ||
| Gastrointestinal effects | 32 | ||
| Ocular effects | 32 | ||
| Psychiatric changes | 32 | ||
| Neurologic effects | 32 | ||
| Opportunistic infections | 32 | ||
| Muscular effects | 32 | ||
| Cutaneous effects | 32 | ||
| Contraindications | 32 | ||
| Pregnancy | 32 | ||
| Clinical use | 32 | ||
| Intramuscular CS | 33 | ||
| Pulse IV CS | 33 | ||
| Intralesional CS | 33 | ||
| Topical CS | 33 | ||
| Monitoring | 33 | ||
| 2.4 Immunomodulatory agents | 33 | ||
| Apremilast | 33 | ||
| Janus kinase inhibitors | 33 | ||
| Tofacitinib | 33 | ||
| Ruxolitinib | 33 | ||
| Azathioprine | 33 | ||
| Mechanism of action | 33 | ||
| 3 General Dermatology | 59 | ||
| Contents list | 59 | ||
| 3.1 Papulosquamous dermatoses | 59 | ||
| Psoriasis | 59 | ||
| Epidemiology | 59 | ||
| Pathogenesis (Fig. 3-1) | 59 | ||
| Clinical features | 61 | ||
| Histopathology | 62 | ||
| Treatment | 62 | ||
| Prognosis/clinical course | 62 | ||
| Additional boards factoids | 62 | ||
| Pityriasis rubra pilaris (PRP) | 62 | ||
| Pathogenesis/epidemiology | 62 | ||
| Clinical features | 62 | ||
| 4 Pediatric Dermatology | 213 | ||
| Contents list | 213 | ||
| 4.1 Neonatal dermatology | 213 | ||
| 4.2 Viral exanthems and select infectious disorders of childhood | 222 | ||
| Rubeola (measles, “First Disease”) | 222 | ||
| Rubella (German measles, “3-day measles,” or “Third Disease”) | 222 | ||
| Erythema infectiosum (“Fifth Disease,” “Slapped cheek disease”) | 223 | ||
| Papular purpuric gloves and socks syndrome | 223 | ||
| Exanthem subitum (roseola infantum, “Sixth Disease”) | 223 | ||
| Hand-foot-and-mouth disease | 224 | ||
| Gianotti-Crosti syndrome (papular acrodermatitis of childhood) | 224 | ||
| Unilateral laterothoracic exanthem (asymmetric periflexural exanthem of childhood) | 224 | ||
| Chronic mucocutaneous candidiasis | 224 | ||
| 4.3 Inherited pigmentary disorders | 225 | ||
| Hypo-/depigmentation | 225 | ||
| Oculocutaneous albinism (OCA) | 225 | ||
| Silvery hair syndromes | 225 | ||
| Hermansky-Pudlak syndrome | 226 | ||
| Piebaldism | 227 | ||
| Waardenburg syndrome | 227 | ||
| Hyperpigmentation | 227 | ||
| McCune-Albright syndrome | 227 | ||
| Reticulate acropigmentation of Kitamura | 228 | ||
| Dowling-Degos disease (DDD) | 228 | ||
| Lentiginoses syndromes | 228 | ||
| Hereditary dyschromatoses | 228 | ||
| Dyschromatosis symmetrica hereditaria (acropigmentation of Dohi) | 228 | ||
| Dyschromatosis universalis hereditaria | 228 | ||
| Dyskeratosis congenita (Zinsser-Engman-Cole syndrome) | 228 | ||
| Naegeli-Franceschetti-Jadassohn syndrome (NFJS)/dermatopathia pigmentosa reticularis (DPR) | 228 | ||
| 4.4 Epidermolysis bullosa (EB) | 230 | ||
| Epidermolysis bullosa (Table 4-10) | 230 | ||
| 4.5 Tumor syndromes | 230 | ||
| Basal cell nevus syndrome (BCNS; Gorlin syndrome) | 230 | ||
| Birt-Hogg-Dubé syndrome | 230 | ||
| Brooke-Spiegler syndrome | 233 | ||
| Multiple endocrine neoplasia (MEN) syndromes | 233 | ||
| Cowden syndrome (multiple hamartoma syndrome) | 234 | ||
| Gardner syndrome | 234 | ||
| 4.6 Vascular tumors, malformations, and related vascular disorders | 234 | ||
| Vascular tumors | 234 | ||
| PHACE syndrome | 234 | ||
| LUMBAR/SACRAL syndrome | 235 | ||
| Neonatal hemangiomatosis | 235 | ||
| Kasabach-Merritt phenomenon | 235 | ||
| Vascular malformations | 235 | ||
| Capillary malformations | 235 | ||
| Capillary malformation (“Port Wine Stain,” PWS, nevus flammeus) | 235 | ||
| Sturge-Weber syndrome (SWS) (encephalotrigeminal angiomatosis) | 235 | ||
| Phakomatosis pigmentovascularis | 236 | ||
| Phakomatosis pigmentokeratotica | 236 | ||
| Klippel-Trenaunay syndrome | 236 | ||
| Proteus Syndrome | 236 | ||
| Beckwith-Wiedemann syndrome | 237 | ||
| Macrocephaly capillary malformation syndrome | 237 | ||
| Venous malformations | 237 | ||
| Maffucci syndrome (Enchondromas with multiple angiomas) | 237 | ||
| Blue-rubber bleb nevus syndrome | 237 | ||
| Glomulovenous malformations (GVM; previously termed “glomangiomas”) | 237 | ||
| Lymphatic malformations | 238 | ||
| Microcystic lymphatic malformations (superficial lymphatic malformation, “lymphangioma circumscriptum”) | 238 | ||
| Macrocystic lymphatic malformations (cystic hygroma) | 238 | ||
| Congenital lymphedema (hereditary congenital lymphedema, Nonne-Milroy syndrome) | 238 | ||
| Arteriovenous malformations (AVMs) | 238 | ||
| AVMs | 238 | ||
| Parkes-Weber syndrome | 239 | ||
| Cobb syndrome (cutaneomeningospinal angiomatosis) | 239 | ||
| Other vascular disorders | 239 | ||
| Cutis marmorata telangiectatica congenita | 239 | ||
| Angiokeratoma corporis diffusum (ACD) | 239 | ||
| Vascular disorders characterized by telangiectasias | 240 | ||
| 4.7 Disorders of hair and nails | 240 | ||
| Pachyonychia congenita | 240 | ||
| Ectodermal dysplasias | 240 | ||
| Hypohidrotic ectodermal dysplasia (Christ-Siemens-Touraine syndrome) | 240 | ||
| Hidrotic ectodermal dysplasia (Clouston syndrome) | 242 | ||
| Ectodermal dysplasias due to p63 mutation | 242 | ||
| Rubinstein-Taybi syndrome | 242 | ||
| 4.8 Inherited metabolic and nutritional disorders | 242 | ||
| Acrodermatitis Enteropathica (genetic form) | 242 | ||
| Biotinidase deficiency and multiple carboxylase deficiency | 246 | ||
| Hartnup disease | 246 | ||
| Phenylketonuria | 246 | ||
| Homocystinuria | 246 | ||
| Lesch-Nyhan syndrome | 247 | ||
| Prolidase deficiency | 247 | ||
| Alagille syndrome | 247 | ||
| Hunter syndrome | 247 | ||
| Alkaptonuria | 247 | ||
| 4.9 Inherited connective tissue disorders | 247 | ||
| Cutis laxa/generalized elastolysis | 247 | ||
| Pseudoxanthoma elasticum | 248 | ||
| Osteogenesis imperfecta (OI) | 249 | ||
| Ehlers-Danlos syndrome (EDS) | 250 | ||
| Marfan syndrome (MFS) | 251 | ||
| Buschke-Ollendorf syndrome | 251 | ||
| Infantile systemic hyalinosis (ISH) and juvenile hyaline fibromatosis (JHF) | 251 | ||
| Lipoid proteinosis (hyalinosis cutis et mucosae, Urbach-Wiethe disease) | 252 | ||
| Focal dermal hypoplasia (Goltz syndrome, Goltz-Gorlin syndrome) | 252 | ||
| Congenital contractual arachnodactyly (Beals syndrome and distal arthrogryposis type 9) | 253 | ||
| Restrictive dermopathy (tight skin contracture syndrome) | 253 | ||
| Stiff Skin syndrome (congenital fascial dystrophy) | 253 | ||
| 4.10 Autoinflammatory disorders (periodic fever syndromes) | 254 | ||
| Epidemiology | 254 | ||
| Pathogenesis | 254 | ||
| Histopathology | 254 | ||
| Treatment | 254 | ||
| Prognosis/clinical course | 254 | ||
| 4.11 Neurocutaneous syndromes | 255 | ||
| Neurofibromatosis (NF) | 255 | ||
| Tuberous sclerosis complex (TSC) | 257 | ||
| Incontinentia pigmenti (IP) | 258 | ||
| 4.12 Premature aging syndromes and dna repair disorders | 259 | ||
| Hutchinson-Gilford progeria | 259 | ||
| Werner syndrome | 260 | ||
| Xeroderma pigmentosum (XP) | 260 | ||
| Bloom syndrome (congenital telangiectatic erythema) | 261 | ||
| Rothmund-Thomson syndrome (Poikiloderma congenitale) | 261 | ||
| Cockayne syndrome (CS) | 261 | ||
| Trichothiodystrophy (Tay syndrome and PIBIDS syndrome) | 262 | ||
| 4.13 Primary immunodeficiency disorders (PIDs) with cutaneous manifestations | 262 | ||
| 4.14 Disorders of cornification | 265 | ||
| 4.15 Miscellaneous pediatric dermatologic disorders | 273 | ||
| Hydroa vacciniforme | 273 | ||
| Actinic prurigo | 273 | ||
| Juvenile spring eruption | 273 | ||
| Diaper dermatitis | 274 | ||
| Juvenile plantar dermatosis | 274 | ||
| Acropustulosis of infancy | 274 | ||
| Cutaneous findings in patients with chromosomal abnormalities | 274 | ||
| Cutaneous mastocytosis | 274 | ||
| Further Reading | 275 | ||
| 5 Infectious Diseases | 279 | ||
| Contents list | 279 | ||
| 5.1 Viral diseases | 279 | ||
| I. Human papillomavirus (HPV) | 279 | ||
| II. Human herpes viruses | 281 | ||
| Herpes simplex virus (HHV-1/HSV-1 and HHV-2/HSV-2) | 281 | ||
| Varicella zoster virus (HHV-3) | 282 | ||
| Epstein-Barr virus (HHV-4) | 283 | ||
| Cytomegalovirus (HHV-5) | 284 | ||
| HHV-6 (Roseola infantum, exanthem subitum, sixth disease) | 284 | ||
| HHV-7 | 284 | ||
| HHV-8 | 284 | ||
| III. Other viruses not covered elsewhere | 285 | ||
| Poxviruses | 285 | ||
| Chikungunya virus | 285 | ||
| Zika virus | 285 | ||
| Dengue virus | 286 | ||
| Viral hepatitides (Table 5-2) | 286 | ||
| Viral-associated trichodysplasia of immunosuppression | 286 | ||
| 5.2 HIV/AIDS dermatology | 287 | ||
| HIV-associated inflammatory dermatoses | 287 | ||
| HIV-associated infectious dermatoses | 287 | ||
| HIV and cutaneous malignancies | 287 | ||
| HIV treatment-associated dermatoses | 288 | ||
| 5.3 Bacterial infections | 288 | ||
| I. Gram-positive skin infections | 288 | ||
| Staphylococcal skin infections | 288 | ||
| Streptococcal skin infections | 290 | ||
| Polymicrobial Gram-positive skin infections | 292 | ||
| Corynebacterial skin infections | 292 | ||
| Clostridium skin infections | 293 | ||
| Filamentous bacteria | 293 | ||
| Other Gram-positive infections | 294 | ||
| II. Gram-negative skin infections | 294 | ||
| Pseudomonas | 294 | ||
| Bartonella | 295 | ||
| Rickettsia | 295 | ||
| Other Gram-negative skin infections | 295 | ||
| III. Nonvenereal spirochete infections | 300 | ||
| Borrelia | 300 | ||
| Nonvenereal (endemic) treponematoses | 300 | ||
| IV. Sexually transmitted bacterial infections | 301 | ||
| Syphilis | 301 | ||
| V. Mycobacterial infections | 302 | ||
| Cutaneous tuberculosis | 302 | ||
| Leprosy (Hansen’s disease) | 304 | ||
| Atypical mycobacteria | 304 | ||
| 5.4 Fungal diseases | 305 | ||
| I. Superficial mycoses | 305 | ||
| Dermatophytes | 305 | ||
| Tinea versicolor (pityriasis versicolor) | 306 | ||
| Piedra | 306 | ||
| Tinea Nigra | 306 | ||
| II. Subcutaneous mycoses | 306 | ||
| Sporotrichosis | 306 | ||
| Lobomycosis | 306 | ||
| Mycetoma | 306 | ||
| Chromoblastomycosis | 307 | ||
| III. Systemic (dimorphic) mycoses | 308 | ||
| Histoplasmosis | 308 | ||
| Blastomycosis (“North American blastomycosis”) | 308 | ||
| Coccidioidomycosis | 308 | ||
| Paracoccidioidomycosis (“South American Blastomycosis”) | 308 | ||
| IV. Opportunistic systemic mycoses | 309 | ||
| Candidiasis | 309 | ||
| Cryptococcosis | 310 | ||
| Aspergillosis | 310 | ||
| Fusarium | 310 | ||
| Penicilliosis | 311 | ||
| V. Uncommon fungal, protozoal and algae pathogens | 311 | ||
| Zygomycosis (mucormycosis) | 311 | ||
| Phaeohyphomycosis | 311 | ||
| Protothecosis | 311 | ||
| Rhinosporidiosis | 311 | ||
| 5.5 Parasites and other creatures | 312 | ||
| Parasitic infestations | 312 | ||
| Scabies | 312 | ||
| Lice | 312 | ||
| Tungiasis (Fig. 5-19) | 312 | ||
| Myiasis | 312 | ||
| Protozoa | 312 | ||
| Leishmaniasis | 312 | ||
| Trypanosomiasis | 314 | ||
| Toxoplasmosis | 314 | ||
| Helminths | 314 | ||
| Cutaneous larva migrans | 314 | ||
| Larva currens | 314 | ||
| Onchocerciasis (“River blindness”) | 314 | ||
| Loiasis | 315 | ||
| Filariasis | 315 | ||
| Swimmer’s itch and Seabather’s eruption | 315 | ||
| Trichinosis | 315 | ||
| Dracunculiasis (Guinea worm) | 315 | ||
| Cutaneous amebiasis | 316 | ||
| Free-living amoeba | 316 | ||
| GI-associated amoeba | 316 | ||
| Bites and stings | 316 | ||
| Biting and stinging insects | 316 | ||
| Arachnids (ticks, mites, spiders, and scorpions) | 316 | ||
| Millipedes and centipedes | 318 | ||
| Snake bites | 318 | ||
| Marine injuries | 318 | ||
| Further Reading | 319 | ||
| 6 Neoplastic Dermatology | 321 | ||
| Contents list | 321 | ||
| Neoplastic dermatology | 321 | ||
| 6.1 Keratinocytic neoplasms | 321 | ||
| Seborrheic keratosis | 321 | ||
| Porokeratosis | 321 | ||
| Epidermal nevus | 322 | ||
| Nevus comedonicus | 323 | ||
| Flegel disease (hyperkeratosis lenticularis perstans) | 323 | ||
| Warty dyskeratoma | 323 | ||
| Premalignant/malignant | 323 | ||
| Actinic keratosis | 323 | ||
| Bowen’s disease (Squamous cell carcinoma in situ) | 323 | ||
| Invasive squamous cell carcinoma | 324 | ||
| Verrucous carcinoma | 324 | ||
| Keratoacanthoma | 324 | ||
| Basal cell carcinoma | 324 | ||
| 6.2 Cysts | 325 | ||
| Epidermoid cyst | 325 | ||
| Trichilemmal (pilar) cyst | 325 | ||
| Proliferating trichilemmal cyst/tumor | 325 | ||
| Dermoid cyst | 325 | ||
| Vellus hair cyst | 325 | ||
| Steatocystoma | 325 | ||
| Hidrocystoma | 326 | ||
| Bronchogenic cyst | 326 | ||
| Thyroglossal duct cyst | 326 | ||
| Median raphe cyst | 326 | ||
| Branchial cleft cyst | 326 | ||
| Pseudocyst of the auricle | 326 | ||
| Omphalomesenteric duct cyst | 326 | ||
| 6.3 Melanocytic neoplasms | 326 | ||
| Ephelides (freckles) | 326 | ||
| CALM (café-au lait macule) | 326 | ||
| Solar lentigo | 327 | ||
| Lentigo simplex | 327 | ||
| Mucosal melanotic macule | 327 | ||
| Dermal melanocytosis | 327 | ||
| Blue nevus | 327 | ||
| Recurrent melanocytic nevus | 327 | ||
| Balloon cell nevus | 328 | ||
| Halo nevus (Sutton nevus) | 328 | ||
| Spitz nevus | 328 | ||
| Pigmented spindle cell nevus of Reed | 328 | ||
| Deep penetrating nevus | 328 | ||
| Congenital melanocytic nevus | 329 | ||
| Nevus spilus/speckled lentiginous nevus | 329 | ||
| Common acquired melanocytic nevus | 329 | ||
| Atypical (dysplastic) melanocytic nevus | 330 | ||
| Becker’s melanosis (NOT a true melanocytic disorder) | 330 | ||
| Melanoma | 330 | ||
| Epidemiology | 330 | ||
| Risk factors | 330 | ||
| Pathogenesis (Boards favorite!) | 330 | ||
| Subtypes | 330 | ||
| Histologic features | 331 | ||
| Prognosis | 331 | ||
| Treatment | 331 | ||
| 6.4 Adnexal neoplasms and hamartomas | 332 | ||
| Eccrine poroma | 332 | ||
| Hidradenoma | 332 | ||
| Syringoma | 333 | ||
| Mixed tumor (chondroid syringoma) | 334 | ||
| Spiradenoma (“eccrine spiradenoma”) | 334 | ||
| Cylindroma | 334 | ||
| Hidradenoma papilliferum (HPAP) | 335 | ||
| Syringocystadenoma papilliferum (SPAP) | 335 | ||
| Papillary eccrine adenoma (PEA) | 335 | ||
| Tubular apocrine adenoma (TAA) | 335 | ||
| Syringofibroadenoma | 335 | ||
| Microcystic adnexal carcinoma (MAC, sclerosing sweat duct carcinoma) | 336 | ||
| Aggressive digital papillary adenocarcinoma | 336 | ||
| Mucinous carcinoma (primary cutaneous) | 336 | ||
| Adenoid cystic carcinoma | 336 | ||
| Comparative dermatopathologic features of sweat gland neoplasms for Board Exam purposes | 337 | ||
| Poroma (classic juxtaepidermal type) | 337 | ||
| Hidroacanthoma simplex | 337 | ||
| Dermal duct tumor | 337 | ||
| Hidradenoma | 337 | ||
| Spiradenoma | 337 | ||
| Cylindroma | 338 | ||
| Syringoma | 338 | ||
| Mixed tumor (chondroid syringoma) | 338 | ||
| Hidradenoma papilliferum (HPAP) | 338 | ||
| Syringocystadenoma papilliferum (SPAP) | 338 | ||
| Papillary eccrine adenoma (PEA) | 338 | ||
| Tubular apocrine adenoma (TAA) | 338 | ||
| Porokeratotic eccrine ostial and dermal duct nevus | 338 | ||
| Syringofibroademoma | 338 | ||
| Microcystic adnexal carcinoma (MAC) | 339 | ||
| Aggressive digital papillary adenocarcinoma | 339 | ||
| Primary cutaneous mucinous carcinoma (PCMC) | 339 | ||
| Adenoid cystic carcinoma | 339 | ||
| 6.5 Hair follicle neoplasms/hamartomas | 339 | ||
| Folliculo-sebaceous-apocrine hamartomas | 339 | ||
| Trichofolliculoma | 339 | ||
| Fibrofolliculoma | 340 | ||
| Nevus sebaceus | 340 | ||
| Neoplasms with follicular germinative differentiation | 341 | ||
| Trichoepithelioma | 341 | ||
| Desmoplastic trichoepithelioma | 341 | ||
| Neoplasms with follicular matrix differentiation | 341 | ||
| Pilomatricoma (calcifying epithelioma of Malherbe) | 341 | ||
| Neoplasms with follicular sheath (trichilemmal) differentiation | 342 | ||
| Trichilemmoma | 342 | ||
| Desmoplastic trichilemmoma | 343 | ||
| Neoplasms with superficial follicular (isthmus and infundibular) differentiation | 343 | ||
| Tumor of the follicular infundibulum | 343 | ||
| Trichoadenoma (of Nikolowski) | 343 | ||
| Proliferating pilar (trichilemmal) tumor | 343 | ||
| 6.6 Sebaceous proliferations | 343 | ||
| Sebaceous hyperplasia | 343 | ||
| Sebaceous adenoma | 343 | ||
| Sebaceoma (sebaceous epithelioma) | 344 | ||
| Sebaceous carcinoma | 344 | ||
| 6.7 Neural neoplasms | 344 | ||
| Traumatic neuroma | 344 | ||
| Palisaded encapsulated neuroma (solitary circumscribed neuroma) | 345 | ||
| Schwannoma (neurilemmoma) | 345 | ||
| Neurofibroma | 345 | ||
| Nerve sheath myxoma (“neurothekeoma”) | 345 | ||
| Cellular neurothekeoma | 345 | ||
| Granular cell tumor | 346 | ||
| Malignant peripheral nerve sheath tumor | 346 | ||
| Merkel cell carcinoma | 346 | ||
| Neuroblastoma | 346 | ||
| 6.8 Smooth muscle neoplasms | 346 | ||
| Pilar leiomyoma | 346 | ||
| Genital leiomyoma | 347 | ||
| Angioleiomyoma | 347 | ||
| Leiomyosarcoma (LMS) | 348 | ||
| 6.9 Hematolymphoid neoplasms | 348 | ||
| Mycosis fungoides | 348 | ||
| Epidemiology | 348 | ||
| Clinical features | 348 | ||
| Histology | 348 | ||
| Treatment | 349 | ||
| Clinical variants | 349 | ||
| Sézary syndrome | 349 | ||
| Adult T-cell leukemia/lymphoma (ATLL) | 349 | ||
| Lymphomatoid papulosis (LyP) | 349 | ||
| Primary cutaneous ALCL (anaplastic large cell lymphoma) | 349 | ||
| Subcutaneous panniculitis-like T-cell lymphoma | 350 | ||
| Primary cutaneous γ/δ T-cell lymphoma | 350 | ||
| Extranodal NK/T-cell lymphoma, nasal type | 350 | ||
| Aggressive epidermotropic cytotoxic (CD8+) T-cell lymphoma | 350 | ||
| Primary cutaneous CD4-positive small/medium pleomorphic T-cell lymphoma | 351 | ||
| Primary cutaneous B-cell neoplasms | 351 | ||
| Leukemia cutis | 351 | ||
| 6.10 Fibrohistiocytic neoplasms | 351 | ||
| Dermatofibroma | 351 | ||
| Dermatofibrosarcoma protuberans | 352 | ||
| Atypical fibroxanthoma (AFX) | 352 | ||
| Other fibroblastic proliferations | 353 | ||
| Angiofibroma | 353 | ||
| Sclerotic fibroma | 353 | ||
| Pleomorphic fibroma | 353 | ||
| Multinucleate cell angiohistiocytoma | 353 | ||
| Epithelioid cell histiocytoma (epithelioid fibrous histiocytoma) | 354 | ||
| Acral fibrokeratoma | 354 | ||
| Dermatomyofibroma | 354 | ||
| Inclusion body fibromatosis (infantile digital fibroma) | 354 | ||
| Fibromatosis | 354 | ||
| Nodular fasciitis | 354 | ||
| Fibrous hamartoma of infancy | 355 | ||
| Myofibroma (infantile myofibromatosis) | 355 | ||
| Giant cell tumor of tendon sheath (Tenosynovial giant cell tumor) | 355 | ||
| Connective tissue nevus (collagenoma and elastoma) | 355 | ||
| 6.11 Vascular proliferations | 356 | ||
| Benign vascular lesions | 356 | ||
| Vascular malformation (includes “port wine stain”, “cavernous hemangioma” old terminology) | 356 | ||
| Intravascular papillary endothelial hyperplasia (Masson’s tumor, pseudoangiosarcoma) | 356 | ||
| Angiokeratoma | 356 | ||
| Infantile hemangioma | 356 | ||
| Pyogenic granuloma (lobular capillary hemangioma) | 356 | ||
| Epithelioid hemangioma (ALHE, angiolymphoid hyperplasia with eosinophils) | 356 | ||
| Hobnail hemangioma (targetoid hemosiderotic hemangioma) | 357 | ||
| Tufted angioma | 357 | ||
| Glomeruloid hemangioma | 357 | ||
| Glomus tumor/glomangioma | 357 | ||
| Borderline vascular neoplasms | 358 | ||
| Kaposiform hemangioendothelioma | 358 | ||
| Kaposi sarcoma | 358 | ||
| Other borderline vascular neoplasms (rare; not commonly tested) | 358 | ||
| High-grade malignant vascular neoplasms | 358 | ||
| Angiosarcoma | 358 | ||
| Vascular neoplasm associations | 359 | ||
| 6.12 Neoplasms of adipocytic lineage | 359 | ||
| Lipoma | 359 | ||
| Angiolipoma | 359 | ||
| Spindle cell/pleomorphic lipoma | 359 | ||
| Hibernoma | 359 | ||
| Well-differentiated liposarcoma (atypical lipomatous tumor) | 359 | ||
| Myxoid/round cell liposarcoma | 361 | ||
| 6.13 Dermoscopy | 361 | ||
| Dermoscopic features of nonmelanocytic lesions (see Table 6-8 and Figs. 6-52 through 6-59) | 361 | ||
| Seborrheic keratosis | 361 | ||
| Basal cell carcinoma | 361 | ||
| Squamous cell carcinoma in situ | 363 | ||
| Squamous cell carcinoma | 363 | ||
| Dermatofibroma | 363 | ||
| Ink spot lentigo | 363 | ||
| Vascular lesions (e.g., cherry angiomas) | 363 | ||
| Hemorrhage | 363 | ||
| Porokeratosis | 363 | ||
| Sebaceous hyperplasia | 363 | ||
| Dermoscopic patterns of melanocytic lesions | 363 | ||
| Further Reading | 366 | ||
| 7 Dermatopathology | 367 | ||
| Contents list | 367 | ||
| 7.1 Essential concepts in dermatopathology | 367 | ||
| Immunofluorescence and related studies (Summarized in Table 7-10, Staining Characteristics of Subepidermal Blistering Diseases) | 376 | ||
| 7.2 High-Yield Dermatopathology Diagnoses at a Glance (Table 7-11) | 378 | ||
| 7.3 High-yield dermatopathology differential diagnoses | 390 | ||
| Infectious processes | 409 | ||
| Further Reading | 414 | ||
| 8 Dermatologic Surgery | 415 | ||
| Contents list | 415 | ||
| 8.1 Surgical anatomy | 415 | ||
| 8.2 Surgical instruments and needles | 420 | ||
| 8.3 Suture techniques | 421 | ||
| 8.4 Wound closure materials | 422 | ||
| 8.5 Local anesthetics and perioperative pain control | 424 | ||
| 8.6 Antisepsis – GARBS and preps | 429 | ||
| 8.7 Electrical hemostasis | 429 | ||
| Introduction | 429 | ||
| Monopolar vs bipolar | 430 | ||
| Monoterminal and biterminal devices | 430 | ||
| Waveforms | 431 | ||
| Electrocautery | 431 | ||
| Electrodesiccation | 431 | ||
| Electrofulguration | 431 | ||
| Electrocoagulation | 431 | ||
| Electrosection | 431 | ||
| Complications | 431 | ||
| Fire hazards | 431 | ||
| Implantable electronic devices | 432 | ||
| 8.8 Cryosurgery | 432 | ||
| 8.9 Excisions | 433 | ||
| 8.10 Mohs surgery | 434 | ||
| 8.11 Flaps | 435 | ||
| 8.12 Grafts | 442 | ||
| 8.13 Surgical complications and measures to avoid them | 444 | ||
| 8.14 Scar improvement | 446 | ||
| Overview | 446 | ||
| Nonsurgical modalities | 446 | ||
| Surgical modalities | 447 | ||
| 8.15 Nail surgery | 448 | ||
| Further Reading | 449 | ||
| 8.1 Surgical anatomy | 449 | ||
| 8.2 Surgical instruments and needles | 449 | ||
| 8.3 Suture techniques | 449 | ||
| 8.4 Wound closure materials | 449 | ||
| 8.5 Local anesthetics and perioperative pain control | 449 | ||
| 8.6 Antisepsis – garbs and preps | 450 | ||
| 8.7 Electrical hemostasis | 450 | ||
| 8.8 Cryosurgery | 450 | ||
| 8.9 Excisions | 450 | ||
| 8.10 Mohs surgery | 450 | ||
| 8.11 Flaps | 450 | ||
| 8.12 Grafts | 450 | ||
| 8.13 Surgical complications and measures to avoid them | 451 | ||
| 8.14 Scar improvement | 451 | ||
| 8.15 Nail surgery | 451 | ||
| 9 Cosmetic Dermatology | 453 | ||
| Contents list | 453 | ||
| 9.1 Lasers | 453 | ||
| Laser safety | 454 | ||
| Vascular lasers | 456 | ||
| Hair reduction lasers and light sources | 457 | ||
| Resurfacing lasers (Table 9-4) | 457 | ||
| Tattoo removal lasers (Table 9-5) | 457 | ||
| 9.2 Botulinum toxin | 458 | ||
| 9.3 Dermal fillers | 459 | ||
| 9.4 Liposuction and fat reduction | 463 | ||
| 9.5 Sclerotherapy | 463 | ||
| 9.6 Cosmeceuticals and nutraceuticals | 465 | ||
| 9.7 Hair transplantation | 465 | ||
| 9.8 Chemical Peels | 465 | ||
| Further Reading | 468 | ||
| 10 Cutaneous Manifestations of Internal Disease and Metastases | 469 | ||
| Contents list | 469 | ||
| 10.1 Cardiovascular/cardiopulmonary | 469 | ||
| Behçet’s disease | 469 | ||
| 11 Epidemiology, Statistics, Study Design, and Public Health Principles | 491 | ||
| Contents list | 491 | ||
| 11.1 Statistical definitions | 491 | ||
| 11.2 Epidemiologic principles | 491 | ||
| 11.3 Types of studies and their limitations | 492 | ||
| 11.4 Types of bias | 493 | ||
| 11.5 Maintenance of certification for the american board of dermatology (see Table 11-2) | 493 | ||
| Further Reading | 494 | ||
| Index | 495 | ||
| A | 495 | ||
| B | 496 | ||
| C | 496 | ||
| D | 497 | ||
| E | 498 | ||
| F | 498 | ||
| G | 499 | ||
| H | 499 | ||
| I | 499 | ||
| J | 500 | ||
| K | 500 | ||
| L | 500 | ||
| M | 500 | ||
| N | 501 | ||
| O | 501 | ||
| P | 501 | ||
| Q | 502 | ||
| R | 502 | ||
| S | 503 | ||
| T | 503 | ||
| U | 504 | ||
| V | 504 | ||
| W | 504 | ||
| X | 504 | ||
| Y | 504 | ||
| Z | 504 | ||
| Inside Back Cover | ibc1 |